Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 6, 2014, Pages 997-1006

  Kong, Chung Yin ^a,b   Kroep, Sonja ⁱ   Curtius, Kit ^c   Hazelton, William D ^f   Jeon, Jihyoun ^e   Meza, Rafael ^g   Heberle, Curtis R ^a   Miller, Melecia C ^a   Choi, Sung Eun ^a   Lansdorp Vogelaar, Iris ⁱ   Van Ballegooijen, Marjolein ⁱ   Feuer, Eric J ^h   Inadomi, John M ^d   Hur, Chin ^a,b   Luebeck, E Georg ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e Program in Biostatistics   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CALIBRATION; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; ESOPHAGEAL ADENOCARCINOMA; MATHEMATICAL MODEL; PRECANCER; PREVALENCE; PRIORITY JOURNAL; SEX RATIO; SIMULATION; UNITED STATES; ADENOCARCINOMA; DISEASE COURSE; ESOPHAGEAL NEOPLASMS; FEMALE; HUMAN; INCIDENCE; MALE; MORTALITY; THEORETICAL MODEL;

ADENOCARCINOMA; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MALE; MODELS, THEORETICAL;

EID: 84903376632     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-1233     Document Type: Article

References (38)

1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-6. (Pubitemid 40277094)
2. Kong CY, Nattinger KJ, Hayeck TJ, Omer ZB, Wang YC, Spechler SJ, et al. The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol Biomarkers Prev 2011;20:2450-6.
3. Thrift AP, Pandeya N, Smith KJ, Green AC, Hayward NK, Webb PM, et al. Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study. Int J Cancer 2012;130:2407-16.
4. Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004; 96:388-96. (Pubitemid 38351300)
5. Thrift AP, Kramer JR, Qureshi Z, Richardson PA, El-Serag HB. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol 2013;108:915-22.
6. Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology 2013;145:312-9e1.
7. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003;138:176-86. (Pubitemid 36231623)
8. Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013;119:1149-58.
9. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 2010;19:1468-70.
10. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;151:716-26, W-236.
11. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:96-104. (Pubitemid 34779153)
12. USPSTF. Screening for Lung Cancer. US Preventive Services Task Force Draft Recommendation Statement 2013;AHRQ Publication No. 13-05196-EF-3.
13. Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst 2010;102:1238-52.
14. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med 2010;153:368-77.
15. SEER. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2011 Sub (1973-2010) - Linked To County Attributes - Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission 2010.
16. Jeon J, Luebeck EG, Moolgavkar SH. Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes Control 2006;17:971-81. (Pubitemid 44078288)
17. Luebeck EG, Curtius K, Jeon J, Hazelton WD. Impact of tumor progression on cancer incidence curves. Cancer Res 2013;73:1086-96.
18. Ruigomez A, Wallander MA, Lundborg P, Johansson S, Rodriguez LAG. Gastroesophageal reflux disease in children and adolescents in primary care. Scand J Gastroenterol 2010;45:139-46.
19. Ruigomez A, Rodriguez LAG, Wallander MA, Johansson S, Graffner H, Dent J. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther 2004;20:751-60. (Pubitemid 39319230)
20. Hur C, Hayeck TJ, Yeh JM, Richards EB, Spechler SJ, Gazelle GS, et al. Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma. PLoS One 2010;5:e9483.
21. Hayeck TJ, Kong CY, Spechler SJ, Gazelle GS, Hur C. The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus 2010;23:451-7.
22. Moolgavkar SH, Holford TR, Levy DT, Kong CY, Foy M, Clarke L, et al. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975- 2000. J Natl Cancer Inst 2012; 104:541-8.
23. Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: Age-period-cohort models. Stat Med 1987;6:469-81. (Pubitemid 17110909)
24. Holford TR. The estimation of age, period and cohort effects for vital rates. Biometrics 1983;39:311-24.
25. Luebeck EG, Moolgavkar SH. Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci U S A 2002;99:15095-100. (Pubitemid 35334615)
26. Kupper LL, Janis JM, Karmous A, Greenberg BG. Statistical age-period-cohort analysis: a review and critique. J Chronic Dis 1985;38:811-30. (Pubitemid 15233757)
27. Holford TR. Understanding the effects of age, period, and cohort on incidence and mortality rates. Annu Rev Public Health 1991;12:425-57.
28. Zheng T, Holford TR, Boyle P, Chen Y, Ward BA, Flannery J, et al. Time trend and the age-period-cohort effect on the incidence of histologic types of lung cancer in Connecticut, 1960-1989. Cancer 1994;74:1556-67. (Pubitemid 24302975)
29. Chu KC, Miller BA, Feuer EJ, Hankey BF. A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. J Clin Epidemiol 1994;47:1451-61.
30. Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS. Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics 2009;27:533-45.
31. Bureau UC. US Census Bureau. US population projections. http://www.census.gov/population/www/projections (last accessed May 1, 2013) 2013.
32. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375-83.
33. Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, et al. The incidence of oesophageal adenocarcinomain non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012;61:970-6.
34. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4:566-72. (Pubitemid 44308164)
35. Hur C, Hayeck TJ, Yeh JM, Richards EM, Spechler SJ, Gazelle GS, et al. Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma. PloS One 2010;5:e9483.
36. Guanrei Y, Songliang Q, He H, Guizen F. Natural history of early esophageal squamous carcinoma and early adenocarcinoma of the gastric cardia in the People's Republic of China. Endoscopy 1988;20:95-8.
37. Cook MB. Optimization and expansion of predictive models for Barrett's esophagus and esophageal adenocarcinoma: could a life-course exposure history be beneficial? Am J Gastroenterol 2013;108:923-5.
38. Shaheen NJ. Editorial: Predicting the risk of Barrett's esophagus: does the BERET fit? Am J Gastroenterol 2013;108:363-5.